Helus Pharma (HELP)
Develops investigational serotonergic therapies for depression and generalized anxiety disorder.
Something off on this page? Send us feedback.
Develops investigational serotonergic agonists for major depressive disorder and generalized anxiety disorder. Its lead programs, HLP003 and HLP004, remain in clinical development, with HLP003 in Phase 3 and HLP004 following a Phase 2 signal-detection study.
Advances HLP003, an adjunctive treatment candidate for major depressive disorder, through the Phase 3 PARADIGM program. APPROACH, EMBRACE, and the EXTEND long-term extension study form that program; HLP003 has FDA Breakthrough Therapy Designation.
Develops HLP004 for generalized anxiety disorder following a Phase 2 signal-detection study, while HLP005 remains before candidate selection. The portfolio is built around novel serotonergic agonists rather than commercial products.
Operates as Helus Pharma while Cybin Inc. remains the legal issuer. The security moved from NYSE American's CYBN to Nasdaq's HELP in 2026, and progress toward commercialization depends on study execution and regulatory approvals.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | Barclays | Initiate | Rating: —Target: — | Target: $35 |
| Jul 27, 2026 | Wells Fargo | Initiate | Rating: —Target: — | Target: $16 |
| Jul 14, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $15 |
| Feb 1, 2026 | Jefferies | Target | Target: — | Target: $22 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $166.2M · Total debt $0 · Total assets $259.3M · Shareholders' equity $241.8M
- Revenue
- $0
- Operating income
- −$47.8M
- Net income
- −$46.6M
No dividends on record.
No ownership filings on record for this listing.
- Definium Therapeutics
Phase 3 lysergide programs in both MDD and GAD
- Compass Pathways (ADR)
Late-stage synthetic psilocybin program for resistant depression
- GH Research
Inhaled mebufotenin program for treatment-resistant depression
- Incannex Healthcare
Oral synthetic psilocybin program for generalized anxiety disorder
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Helus Pharma | $13.20 | −3.72% | $849.8M | — | — | — | — |
| Definium Therapeutics | $37.86 | −6.11% | $5.35B | — | — | — | — |
| Compass Pathways (ADR) | $14.16 | −4.19% | $1.99B | — | — | — | — |
| GH Research | $26.95 | −3.27% | $1.91B | — | — | — | — |
| Incannex Healthcare | $3.52 | +3.71% | $40.6M | — | — | — | +1,566.7% |
| Median | — | — | — | +1,566.7% |